IGF2 Antibody

What is IGF2 and why is it significant for research?

IGF2 (insulin-like growth factor 2) is one of the most abundant growth factors in the human body and the most abundant peptide with insulin-activity. It may also be referred to by alternative names including preptin, C11orf43, GRDF, IGF-II, PP9974, insulin-like growth factor II, and T3M-11-derived growth factor . The protein has a molecular weight of approximately 20.1 kilodaltons . Despite its abundance, IGF2 has been relatively understudied compared to related proteins such as insulin and IGF1, with approximately one-third the number of publications of IGF1 and one-thirtieth those of insulin . This discrepancy exists despite IGF2 having more complex genetics and signaling mechanisms, suggesting its biological importance may be underappreciated. Research on IGF2 is particularly significant in the context of cancer biology, where it has been implicated in drug resistance mechanisms in several cancer types .

What forms of IGF2 exist in biological systems?

IGF2 exists in multiple forms throughout its processing pathway, which is important to consider when designing experiments and selecting antibodies. The protein is initially synthesized as a 21 kDa pre-pro-protein, which is cleaved into a 15 kDa pro-protein. This pro-protein undergoes several post-translational modifications to produce the mature 7 kDa peptide that is rapidly secreted from cells . When working with IGF2 antibodies, researchers should consider which form of the protein they intend to detect. Western blot analysis typically reveals the 15 kDa pro-IGF2 within cells, while detection of the mature 7 kDa peptide often requires analysis of conditioned media or specialized collection techniques due to its rapid secretion . Understanding these different forms is crucial for experimental design and accurate data interpretation, as antibodies may have differential affinity for these various processed forms.

What are the common applications for IGF2 antibodies?

IGF2 antibodies are utilized across a wide range of experimental applications in research settings. Based on commercially available products, the most common applications include Western Blot (WB), Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Immunofluorescence (IF), and Immunoprecipitation (IP) . Other less common but still significant applications include Flow Cytometry (FCM), Functional Assays (FA), and Neutralization (Neut) . When selecting an IGF2 antibody, researchers should verify that the antibody has been validated for their specific application of interest. Validation typically involves demonstrating specificity through appropriate controls and confirming reactivity with the target species. Most commercial IGF2 antibodies are available with reactivity against human IGF2, though many also cross-react with mouse and rat orthologs owing to high sequence conservation .

How do IGF2 antibodies contribute to understanding drug resistance mechanisms in cancer?

IGF2 antibodies serve crucial functions in investigating these resistance mechanisms. They enable researchers to quantify IGF2 protein levels in patient samples via immunohistochemistry, correlating expression with clinical outcomes. In experimental settings, antibodies allow for Western blot verification of successful IGF2 knockdown when testing sensitization strategies. Neutralizing IGF2 antibodies can functionally block the protein to evaluate its direct role in drug resistance pathways. When studying IGF2-mediated resistance, researchers should consider that IGF2 knockdown restored Taxol sensitivity more effectively than targeting the IGF1R receptor alone, suggesting that direct IGF2 targeting might be a superior therapeutic strategy .

What considerations are important when using IGF2 antibodies for detecting different species orthologs?

When utilizing IGF2 antibodies across different species, researchers must account for sequence homology and conservation of epitopes. Based on gene name and sequence analysis, IGF2 antibodies may detect orthologs in canine, porcine, monkey, mouse and rat models, though with varying efficacy . This cross-reactivity stems from evolutionary conservation of the IGF2 protein structure across mammals.

• Epitope accessibility may differ between species due to variations in post-translational modifications

• Antibody affinity often varies across species, potentially requiring higher concentrations for non-human applications

• The degree of processing from pro-IGF2 to mature IGF2 may differ between species, affecting which form predominates

When adapting protocols from human to animal models, validation experiments are essential. These should include positive and negative controls specific to the target species and comparison with known expression patterns. For studies requiring precise cross-species comparisons, selecting antibodies raised against highly conserved epitopes is recommended. Alternatively, species-specific antibodies may be necessary when studying regions with greater sequence divergence.

How can IGF2 antibodies be used to study the complex relationship between IGF2 and its binding proteins?

IGF2 biology is complicated by its interactions with multiple binding proteins, with several binding IGF2 with higher affinity than IGF1 . This complexity presents both challenges and opportunities for researchers using IGF2 antibodies to study these interactions. When investigating IGF2-binding protein relationships, researchers should consider:

• Antibody epitope location relative to binding protein interaction sites

• Whether the antibody recognizes free IGF2, bound IGF2, or both

• The potential for binding proteins to mask antibody recognition sites

Methodological approaches for studying these interactions include co-immunoprecipitation experiments using IGF2 antibodies to pull down binding protein complexes. Researchers can also employ proximity ligation assays to visualize and quantify interactions in situ within tissues or cells. When interpreting results, it's important to recognize that high-affinity binding proteins may sequester IGF2, potentially reducing antibody detection in direct assays. This can lead to underestimation of total IGF2 levels unless samples are pretreated to dissociate these complexes.

For accurate quantification of total IGF2 (both free and bound), researchers should consider acid-ethanol extraction protocols that disrupt binding protein interactions prior to antibody-based detection. Alternatively, designing experiments with antibodies targeting epitopes that remain accessible even when IGF2 is bound to its binding proteins can provide valuable insights into the dynamics of these interactions.

How should researchers select the appropriate IGF2 antibody for their specific experimental needs?

Selecting the optimal IGF2 antibody requires systematic evaluation of multiple factors aligned with experimental objectives. Given the variety of available antibodies (over 598 IGF2 antibodies from 36 suppliers) , researchers should consider:

• Antibody Type and Format

  • Monoclonal vs. polyclonal: Monoclonals offer higher specificity for particular epitopes, while polyclonals provide broader recognition but potential higher background

  • Host species: Consider compatibility with other antibodies in multi-label experiments

  • Conjugation needs: Determine whether unconjugated or directly labeled (FITC, HRP, Alexa dyes) antibodies are required

• Target Specificity

  • Epitope location: Antibodies targeting different regions of IGF2 will detect different forms (pro-IGF2 vs. mature IGF2)

  • Cross-reactivity: Verify specificity against related proteins like IGF1 and insulin

  • Species reactivity: Confirm validation in your experimental species (human, mouse, rat, etc.)

• Application Validation

  • Verify the antibody has been specifically validated for your application (WB, IF, IHC, IP, ELISA)

  • Review published literature using the same antibody in similar applications

  • Examine supplier validation data including positive and negative controls

For quantitative applications like western blotting or ELISA, antibodies with established standard curves and known detection limits are preferable. For localization studies, antibodies validated for specificity in immunohistochemistry or immunofluorescence should be prioritized. When studying protein interactions, antibodies with epitopes outside binding domains may be necessary to avoid interference with natural binding events.

What controls are essential when working with IGF2 antibodies?

Establishing appropriate controls is fundamental to ensuring the reliability and interpretability of experiments utilizing IGF2 antibodies. Essential controls include:

• Positive Controls

  • Cell lines or tissues known to express IGF2 (placental tissue is often used as a high-expression positive control)

  • Recombinant IGF2 protein for calibration in quantitative assays

  • IGF2-overexpressing transfected cells to verify antibody sensitivity

• Negative Controls

  • IGF2 knockout or knockdown samples to confirm specificity

  • Secondary antibody-only controls to assess non-specific binding

  • Isotype controls matched to the primary antibody's host species and isotype

  • Pre-absorption controls where the antibody is pre-incubated with excess antigen

• Technical Controls

  • Loading controls for western blots (β-actin, GAPDH)

  • Internal standardization with housekeeping proteins for immunohistochemistry

  • Concentration gradients to establish the linear detection range

What detection methods yield optimal results with IGF2 antibodies?

Detection methodologies for IGF2 antibodies must be optimized based on the protein's unique characteristics, including its multiple processed forms and potential interactions with binding proteins. Researchers should consider the following approach-specific considerations:

• Western Blotting

  • Sample preparation: Acid-ethanol extraction may be necessary to dissociate IGF2 from binding proteins

  • Buffer systems: Tris-Tricine gels are recommended for detecting the mature 7 kDa IGF2 peptide

  • Transfer conditions: Semi-dry transfer with PVDF membranes typically yields better results for smaller IGF2 forms

  • Expected bands: Primary bands at approximately 15 kDa (pro-IGF2) and 7 kDa (mature IGF2)

• Immunohistochemistry/Immunofluorescence

  • Fixation: Paraformaldehyde fixation typically preserves IGF2 epitopes better than alcohol-based fixatives

  • Antigen retrieval: Citrate buffer pH 6.0 heat-induced retrieval is generally effective

  • Signal amplification: Tyramide signal amplification may be necessary for detecting low abundance IGF2

  • Counterstaining: Consider nuclear counterstains that won't interfere with cytoplasmic IGF2 localization

• ELISA and Quantitative Assays

  • Sample preparation: For serum/plasma, acid-ethanol extraction improves detection of total IGF2

  • Assay format: Sandwich ELISA using capture and detection antibodies targeting different epitopes improves specificity

  • Standard curve: Recombinant human IGF2 standards should include both pro-IGF2 and mature IGF2 forms

  • Cross-reactivity: Validate absence of interference from IGF1 and insulin in quantitative assays

For detecting secreted mature IGF2 in cell culture, conditioned media should be concentrated prior to analysis, as the 7 kDa form is rapidly secreted and may be below detection limits in unconcentrated samples . When studying IGF2 in complex tissues, consider multiplexed immunofluorescence to simultaneously visualize IGF2 and its binding partners or receptors.

How should researchers address inconsistent results when using IGF2 antibodies?

Inconsistent results with IGF2 antibodies can stem from multiple factors related to the protein's biology and experimental conditions. When encountering variability, systematic troubleshooting should address:

• Biological Variability Sources

  • IGF2 processing differences: The relative abundance of 21 kDa pre-pro-protein, 15 kDa pro-protein, and 7 kDa mature forms varies across tissues and conditions

  • Expression regulation: IGF2 expression is subject to complex genetic regulation including genomic imprinting

  • Binding protein interactions: Varying levels of binding proteins can sequester IGF2 and affect detection

  • Post-translational modifications: Glycosylation patterns may alter epitope accessibility

• Technical Causes and Solutions

  • Antibody degradation: Implement aliquoting and proper storage protocols (avoid freeze-thaw cycles)

  • Batch variation: Use consistent antibody lots when possible or revalidate with lot changes

  • Inconsistent sample preparation: Standardize protein extraction and processing methods

  • Detection system variability: Calibrate imaging or plate reader systems regularly

When comparing results across experiments, researchers should normalize data to appropriate controls and consider expressing results as fold changes rather than absolute values. For IGF2 quantification in comparative studies, running all samples in a single experiment minimizes inter-assay variability. If systematic differences persist despite standardization efforts, antibody validation using orthogonal methods (such as mass spectrometry or nucleic acid-based detection of IGF2) can help clarify whether variability reflects true biological differences or technical artifacts.

What are the most common pitfalls when interpreting IGF2 antibody results in cancer research?

Cancer research utilizing IGF2 antibodies presents specific interpretive challenges that researchers should approach with caution. Common pitfalls include:

• Confounding by Tissue Heterogeneity

  • Tumor samples contain varying proportions of cancer cells, stromal cells, and immune infiltrates

  • IGF2 expression may come from tumor cells, cancer-associated fibroblasts, or other stromal components

  • Solution: Use double immunolabeling to identify the specific cell types expressing IGF2

• Misinterpretation of IGF2's Role in Drug Resistance

  • Association versus causation: High IGF2 expression correlates with drug resistance but may not be the primary driver

  • Pathway redundancy: Other growth factors may compensate when IGF2 is inhibited

  • Solution: Combine antibody detection with functional studies (knockdown/overexpression) to establish causality

• Overlooking Receptor Interactions

  • IGF2 binds multiple receptors including IGF1R, insulin receptor, and the IGF2R/mannose-6-phosphate receptor

  • Each receptor interaction may trigger different downstream signaling

  • Solution: Assess receptor expression and activation status alongside IGF2 levels

• Challenges in Quantitative Comparison

  • Different antibodies and detection methods yield different "normal" ranges

  • Solution: Include calibration standards and consistent controls across experiments

How can researchers differentiate between specific and non-specific signals when using IGF2 antibodies?

Distinguishing specific from non-specific signals is critical for accurate IGF2 detection and quantification. Researchers should implement the following strategies:

• Validation Through Multiple Approaches

  • Confirm specificity through at least two independent antibodies targeting different epitopes

  • Correlate protein detection with mRNA expression data when possible

  • Verify signal reduction following IGF2 knockdown or knockout

  • Compare patterns to known IGF2 expression profiles in literature

• Technical Approaches to Minimize Background

  • Optimize blocking conditions: Evaluate different blocking agents (BSA, milk, serum) for lowest background

  • Titrate antibody concentrations to determine optimal signal-to-noise ratio

  • Adjust incubation conditions: Longer incubation at 4°C often provides better specificity than shorter incubation at room temperature

  • Pre-absorb antibodies with recombinant IGF2 to confirm signal specificity

• Pattern Recognition for Specific Signals

  • In Western blots: Expect bands primarily at 15 kDa (pro-IGF2) and potentially 7 kDa (mature IGF2)

  • In IHC/IF: Compare subcellular localization to expected patterns (predominantly cytoplasmic/secretory)

  • In ELISA: Establish standard curves and detection limits with recombinant protein

• Advanced Validation for Critical Applications

  • For therapeutic development: Validate with mass spectrometry or N-terminal sequencing

  • For diagnostic applications: Compare antibody detection with established clinical biomarkers

  • For mechanistic studies: Confirm functionality with neutralization experiments

When investigating IGF2 in drug resistance contexts, researchers should be particularly vigilant about non-specific signals in resistant cell lines, which often have altered protein expression profiles. Comparative analysis between sensitive and resistant lines should include appropriate loading controls and normalization strategies to account for these differences .